Custom and Small-Lot Intermediates: How a Project-Driven Order Actually Runs

Some intermediates are bought on a catalogue line and shipped the same week. Others – isatin-3-oxime (CAS 607-28-3) is a good example – only exist inside a project: one customer, one route, one specification, a quantity in the tens of kilograms, and a repeat order next year if the programme survives. Those two situations need completely different supplier conversations, and buyers who run the second one through a catalogue process usually get a bad outcome on both sides. This article is about how a project-driven order actually runs, and what to settle at each stage.

1. Three stages, three different questions

Stage	Typical quantity	What the buyer actually needs	Where it goes wrong
Route screening	Grams	Speed, a usable certificate, and honesty about what is not yet controlled	Supplier quotes a catalogue grade the material has never been made to
Process development	Hundreds of grams to a few kilograms	Batch-to-batch consistency, so the next experiment is comparable with the last	Second lot differs because “it is the same product” was treated as a specification
Commercial campaign	Tens to hundreds of kilograms	A written specification, a production slot, and a documented change-control path	No written spec, so any drift is arguable

The most expensive mistake is treating stage 1 as a small version of stage 3. A gram sample tells you the chemistry works and the supplier exists. It does not tell you the process is repeatable at scale, and it is not evidence that the specification will still be met in a year.

2. Why the specification matters more than the assay

Take a typical catalogue entry for this kind of intermediate: appearance, purity 99% min. That is a sales figure, not a manufacturing specification. What a downstream pharmaceutical or agrochemical customer actually needs is the set of tests that predict whether the next step will work in their hands:

What the catalogue shows	What the process needs	Why
Appearance	Appearance plus a colour limit	Colour drift is the earliest visible sign of a process change
Purity 99% min	Purity plus the named impurities that matter to this route	For isatin-3-oxime, residual isatin is the obvious one
–	Water content	Converts a dry-basis assay into what you actually receive
–	Residual solvent set	Regulated-market limits are specific; “none detected” is not a limit
–	Isomer or tautomer ratio where relevant	For an oxime, the E/Z ratio is set by the process and can change the downstream step

On the first lot, agree this list with the supplier and write it down. On the second lot, hold them to it. Everything in between is a favour, not a supply arrangement.

3. What to put in the enquiry

Field	Example entry	Why the supplier needs it
Product and CAS	Isatin-3-oxime, CAS 607-28-3	Removes ambiguity between the 2- and 3-oxime, which are different compounds
Quantity and shape	5 kg now, 25 kg per year for three years if the programme continues	Decides whether this is a lab batch or a campaign, and therefore the price
Specification	Purity 99% min, residual isatin under 0.5%, water under 0.5%	Anything not stated will be whatever the process happens to give
Documentation	COA with method statements; SDS in English; third-party testing on the first lot	Documentation is a deliverable, and it has a lead time of its own
End use and destination	Pharmaceutical intermediate, Germany; customs classification required	Changes the required paperwork and the packaging
Timeline	Needed for a pilot campaign starting in ten weeks	A custom batch competes for a production slot; early notice is the only lever

Six fields. Filled in properly, they produce quotations that can be compared. Left out, they produce three prices that mean different things, followed by a second round of questions that costs everyone two weeks.

4. The five mistakes buyers make with custom intermediates

Buying on price per kilogram. At these volumes, the cost of one failed lot – rework, delayed campaign, re-qualification – dwarfs any plausible price difference between two suppliers.
Not naming the impurity that matters. A 99% assay can hide the one impurity your next step cannot tolerate.
Assuming the second batch equals the first. Ask, in writing, that repeat lots be made to the written specification. “Same product” is not a control.
Sending the route before the NDA. If the specification reveals your chemistry, the commercial conversation should happen under confidentiality – and a supplier who does not raise this first is telling you something.
Treating lead time as a promise. For a custom item the lead time is a production slot. Ask what happens if your schedule moves, and what happens if theirs does.

5. What “we can customise” should actually mean

Almost every supplier claims customisation. The claims worth testing are narrower:

Can they write a specification rather than quote a catalogue one?
Can they hold it across lots and show the historical data?
Can they scale between the quantity you tested and the quantity you will buy without the material changing?
Can they supply the paperwork the destination market requires, not just a generic SDS?
Will they still take the order when it is twenty kilograms rather than a tonne?

That last point is where most “custom synthesis” offers quietly fail. A kilogram-scale order with a written specification is unattractive to a plant set up for tonne batches, and is exactly the order that a project-driven programme needs first.

6. The scale reality behind a molecule like isatin-3-oxime

It is worth stating plainly: the annual global requirement for an intermediate of this kind is measured in tens of kilograms, not thousands of tonnes. It exists because a specific route needs it, and it will keep existing as long as that route or its successors do. That has two consequences for a buyer. First, the supplier relationship is more durable than the price – the material will not be re-quoted across ten suppliers every quarter. Second, the useful thing to negotiate is not a discount but a written specification plus a production commitment, because availability at the moment your campaign starts is worth more than a percentage.